Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$5.9 - $8.02 $6,490 - $8,822
-1,100 Reduced 64.71%
600 $3,000
Q1 2024

May 15, 2024

SELL
$7.5 - $12.07 $42,000 - $67,592
-5,600 Reduced 76.71%
1,700 $14,000
Q4 2023

Feb 14, 2024

SELL
$6.01 - $11.48 $20,434 - $39,032
-3,400 Reduced 31.78%
7,300 $80,000
Q3 2023

Nov 14, 2023

SELL
$8.24 - $12.97 $88,168 - $138,779
-10,700 Reduced 50.0%
10,700 $89,000
Q2 2023

Aug 14, 2023

SELL
$9.99 - $18.27 $474,525 - $867,825
-47,500 Reduced 68.94%
21,400 $268,000
Q1 2023

May 15, 2023

BUY
$15.0 - $22.76 $1.03 Million - $1.56 Million
68,700 Added 34350.0%
68,900 $1.13 Million
Q4 2022

Feb 14, 2023

SELL
$14.16 - $24.02 $158,592 - $269,024
-11,200 Reduced 98.25%
200 $2,000
Q3 2022

Nov 14, 2022

BUY
$18.07 - $31.37 $205,998 - $357,618
11,400 New
11,400 $255,000

Others Institutions Holding RLAY

About Relay Therapeutics, Inc.


  • Ticker RLAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 120,219,000
  • Market Cap $780M
  • Description
  • Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...
More about RLAY
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.